CRP and ankylosing spondylitis: High levels of CRP at baseline also predicted improved adalimumab persistence at 24 months in our hands, a finding that has also been observed previously in ankylosing spondylitis (Glintborg et al., 2010) as well as PsA patients (Glintborg et al., 2011; Aaltonen et al., 2017).